Evogene initiated with a Buy at Lake Street

Lake Street analyst Ben Klieve initiated coverage of Evogene with a Buy rating and $2 price target. Evogene – with five unique subsidiaries throughout agriculture, human health, and biofuel markets – is "a diversified opportunity with multiple high-value shots on goal but a deeply discounted valuation," the analyst tells investors. The firm sees visibility to a steep commercial ramp at three of five subsidiaries, the analyst added.